MNMD250117C2000
- 5.85
- 0.000.00%
Mind Medicine Newsroom
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
Mind Medicine Price Target Announced at $20.00/Share by Chardan Capital
Mind Medicine Initiated at Buy by Chardan Capital
Mind Medicine to Join Nasdaq Biotechnology Index
Express News | MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024
Mind Medicine Analyst Ratings
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
Mind Medicine (MNMD) Receives a Buy From Oppenheimer
MindMed Doses First Patient in Phase 3 Trial of LSD Trial for Anxiety
Express News | Mind Medicine (MindMed) Inc - Panorama Study to Initiate in U.S. and Europe in First Half of 2025
Express News | MindMed Announces First Patient Dosed in Phase 3 Voyage Study of Mm120 in Generalized Anxiety Disorder (Gad)
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Mind Medicine Gets UK's Innovation Passport Designation for Investigational Anxiety Disorder Treatment
Express News | Mind Medicine: Awarded Innovation Passport Designation by UK Ilap Steering Group for Mm120 Odt for Generalized Anxiety Disorder
Express News | MindMed Appoints Javier Muniz, M.d., as Vice President of Research and Development Strategy
MindMed Announces New Employee Inducement Grants
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
Mind Medicine Appoints Gregg Pratt Chief Regulatory, Quality Assurance Officer
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading Into 2025?